BioSpace News Archive

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EMT”), an innovator and manufacturer of single-use silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molded and over-molded connectors and silicone tubing products

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has been added to the Russell 3000 ® and Microcap ® Indexes at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stock

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held from July 12-14, 2020. Presentation details: Poster Title: Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia (PB0941)

Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the Russell 2000 ® Index effective at the U.S. market open today, June 29, 2020. The Annual Russell index reconstitution captures the 4,000 largest US stocks as of May 8, ranking them by total market capitalization. Membership in the U.S. Russell 2000 Index ® remains in place for one year and also means automatic inclusion in the appropriate gro

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). F

Masimo (NASDAQ: MASI) today announced Bridge™, an opioid withdrawal solution that uses neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal. Bridge, which has been granted an FDA De Novo classification, is the first evidence-based, drug-free, non-surgical device of its kind. This press release features

Kyocera Corporation and Tokyo Medical and Dental University (TMDU) announced a joint research project to develop a wireless headset that can remotely monitor high accuracy patient biometrics, such as blood oxygen saturation (SpO2). The Department of Cardiovascular Medicine of TMDU Medical Hospital began preparing for clinical research of the wearable headset system in May 2020. This press release features multimedia. View

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has closed on the sale of 2,187,500 shares of the Company’s common stock, at a purchase price of $8.00 per share, in a registered direct offering. The closing of the offering occurred on June 26, 2020. The gross proceeds to the Company from this offering were $17.5 million, before dedu

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it was added to the Russell 3000 ® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution. “Genprex is excited to

Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, today announced that it has been added to the U.S. broad-market Russell 3000® and Russell 2000® Indices, effective at the market close on June 26, 2020 as part of FTSE Russell’s annual index reconstitution. The Russell 3000® index measures the perform